Core Viewpoint - The commercialization of Phosphate Oglazostatin Tablets (brand name: Shiruisa) marks a significant advancement in the treatment of Cushing's syndrome in China, filling a gap in the market for oral medications for this rare disease [1] Group 1: Product Launch and Approval - Phosphate Oglazostatin Tablets are the only approved oral medication for adult Cushing's syndrome in China, officially launched on April 12 [1] - The drug is a First-in-Class innovation from Recordati Group's subsidiary in China, and has received orphan drug designation in the US, EU, and Australia [1] - The drug was granted priority review and approval by the National Medical Products Administration (NMPA) in September 2023, with import approval expected in September 2024 [1] Group 2: Clinical Efficacy and Safety - Global clinical studies have demonstrated the efficacy and safety of Phosphate Oglazostatin Tablets, with a three-phase clinical trial involving 210 patients showing significant cortisol level reduction and sustained efficacy for over four years [1] - Chinese patients exhibit higher sensitivity to the drug, requiring approximately half the daily dosage compared to patients in Europe and the US [1] Group 3: Impact on Treatment Paradigm - The introduction of the new drug is expected to optimize surgical outcomes for Cushing's syndrome, allowing non-surgical patients the opportunity for surgery and improving the physical condition of surgical candidates [2] - The focus of treatment is shifting towards comprehensive recovery for patients, addressing not only cortisol levels but also the broader impacts of Cushing's syndrome, including cardiovascular risks and psychological health [2] - The recurrence rate post-surgery can be as high as 25% over ten years, prompting a shift towards a "one-time Cushing's, lifelong follow-up" treatment model, which the new drug will facilitate [2]